GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells $362,565.79 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 3,749 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $96.71, for a total value of $362,565.79. Following the completion of the transaction, the chief financial officer now owns 8,492 shares in the company, valued at $821,261.32. The trade was a 30.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Thursday, March 13th, Kevin Feeley sold 402 shares of GeneDx stock. The stock was sold at an average price of $90.05, for a total value of $36,200.10.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The shares were sold at an average price of $94.72, for a total value of $87,331.84.
• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total value of $21,582.00.
• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The shares were sold at an average price of $93.82, for a total value of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The stock was sold at an average price of $76.04, for a total value of $108,737.20.

GeneDx Trading Down 4.1 %

Shares of GeneDx stock opened at $94.46 on Tuesday. The stock has a fifty day simple moving average of $84.69 and a 200 day simple moving average of $70.37. GeneDx Holdings Corp. has a 12-month low of $7.72 and a 12-month high of $115.60. The company has a market capitalization of $2.65 billion, a P/E ratio of -48.19 and a beta of 1.91. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The business had revenue of $95.64 million for the quarter, compared to analysts’ expectations of $82.24 million. On average, sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on WGS. The Goldman Sachs Group lifted their price objective on GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 19th. TD Cowen boosted their price objective on GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $72.33.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. MCF Advisors LLC lifted its position in shares of GeneDx by 107.7% during the 4th quarter. MCF Advisors LLC now owns 351 shares of the company’s stock valued at $27,000 after buying an additional 182 shares during the last quarter. Sterling Capital Management LLC lifted its holdings in GeneDx by 877.8% during the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock worth $27,000 after purchasing an additional 316 shares in the last quarter. Global Retirement Partners LLC bought a new position in GeneDx in the 4th quarter worth about $28,000. Lazard Asset Management LLC bought a new position in GeneDx in the 4th quarter worth about $35,000. Finally, Comerica Bank bought a new position in GeneDx in the 4th quarter worth about $50,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.